Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

134.63 -0.92 (-0.68%)
Streaming Delayed Price Updated: 2:54 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
44 45 Next >
2 High-Yield Dividend Stocks to Buy in March
Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years. 
Via The Motley Fool
ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT
From Kahn Swick & Foti, LLC
Via Business Wire
1 High-Flying Growth Stock With 19% Upside, According to Wall Street
This company could keep going up, but beware of the risks. 
Via The Motley Fool
Dexcom Nears Breakout On A Surprise Medicare Decision For Its Devices
The decision came months ahead of Dexcom's and Abbott's expectations. 
Via Investor's Business Daily
Build Your Wealth by Buying and Holding These 2 Dividend Stocks for at Least 20 Years
The road to wealth is long, but it'll be a bit shorter with the right investments. 
Via The Motley Fool
Why Cardiovascular Systems Stock Is Soaring Today
The medtech company has agreed to a buyout offer from Abbott Laboratories. 
Via The Motley Fool
Get a Dividend Every Month With These 3 Healthcare Stocks
With a little planning, you can receive a dependable dividend payout every month. 
Via The Motley Fool
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its 
Via MarketBeat
Topics Initial Public Offering
Exposures COVID-19 Product Safety Securities Market
Why Abbott Laboratories Stock Bumped Higher Today
The company's specialized heart care products appear to prove their value in clinical testing. 
Via The Motley Fool
How Is The Market Feeling About Abbott Laboratories?
Abbott Laboratories's (NYSE:ABT) short percent of float has risen 11.43% since its last report. The company recently reported that it has 13.19 million shares sold short, which is 0.78% of all regular... 
Via Benzinga
Should Abbott and DexCom Investors Be Worried About Apple's Latest News?
The continuous glucose monitoring market could heat up. 
Via The Motley Fool
Better Dividend Stock: Abbott Laboratories or Medtronic?
One of these top dividend stocks is a far more compelling buy today. 
Via The Motley Fool
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Better Buy: Abbott Laboratories or DexCom Stock?
Both stocks should benefit from the growth in diabetes care. 
Via The Motley Fool
Why Abbott Laboratories Stock Sank Today
The company's glucose monitoring business might come under some serious pressure. 
Via The Motley Fool
What Does Apple Have To Do With DexCom Stock Trading Lower?
DexCom shares (NASDAQ: DXCM) are trading lower on Wednesday following a report that Apple Inc (NASDAQ: AAPL) is making progress on no-prick glucose tracking for its Watch. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
From Brodsky & Smith LLC
Via GlobeNewswire
3 Top Dividend Kings to Buy for the Long Haul
These companies have more than 150 years of dividend growth between them. 
Via The Motley Fool
2 Exceptional Growth Stocks Billionaires Keep Buying With Both Hands
A poor performance from the broad market didn't stop these billionaire hedge fund managers from placing big bets on three supercharged growth stocks. 
Via The Motley Fool
Interview With David Rolfe of Wedgewood Partners
Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe. 
Via The Motley Fool
I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.
We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right? 
Via InvestorPlace
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. 
Via MarketBeat
7 Hot Healthcare Stocks With the Potential to Outperform
These healthcare stocks to buy now have the potential to outperform the market over the long-term because their businesses are strong. 
Via InvestorPlace
Which Healthcare Stock Is a Better Pick in 2023?
With a potential recession on the horizon, healthcare stocks could be good picks for investors. Which of these three is best? 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
From Brodsky & Smith LLC
Via GlobeNewswire
Better Buy: Johnson & Johnson or AbbVie?
The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead. 
Via The Motley Fool
Candy? Flowers? These Top Stocks Offer You Something Even Sweeter
These stocks may reward you over time. 
Via The Motley Fool
The 7 Most Undervalued Dividend Aristocrats to Buy
With so many uncertainties ahead, investors may take comfort in the stability of the most undervalued dividend aristocrats to buy. 
Via InvestorPlace
Abbott-Cardiovascular Systems Acquisition Could Further Add Uncertainty Over Surmodics' Product: Analyst Downgrades Stock
Via Benzinga
Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million
Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and 
Via Spotlight Growth
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.